Morphiex Biotherapeutics | Anthony Schwartz, PhD CEO
556
page-template-default,page,page-id-556,ajax_fade,page_not_loaded,,qode-title-hidden,qode-content-sidebar-responsive,qode-theme-ver-13.8,qode-theme-bridge,disabled_footer_top,disabled_footer_bottom
Anthony Schwartz, PhD
Chief Executive Officer

Dr. Schwartz has over 15 years of experience in the biotechnology industry founding over 10 startups and serving in executive positions of Athencion Biotech, Interthyr Corp, XTELL Corp and BioVisors Consulting. He has raised millions in non-diluted funding, supported the development of an FDA approved diagnostic and a moved pipeline of oncology and autoimmune therapeutics through IND. He worked with the National Institutes of Health/National Cancer Institute to advance Morphiex’s lead CD47 asset, MBT-001, into the clinic and is considered a Key Opinion Leader in the CD47 space. He is also a Professor at The Johns Hopkins University, published multiple publications in prestigious journals and holds patents on a class of drugs attenuating the immune system for the treatment of cancer and diabetes. Anthony received his Ph.D. from Colorado State University in Biomedical Engineering with research focused on the immune system’s role in cancer, novel radiation therapies and stem cells.

Location

240 Newbury Street, 2nd Floor
Boston, MA
info@morphiex.com

Social Media

Twitter Facebook LinkedIn